Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas

Investigational New Drugs

Volumn 13, Issue 4, 1995, Pages 347-354

  Scher, Richard M ^a,b   Kosierowski, Richard ^a,b   Lusch, Charles ^a,b   Alexander, Roland ^a,b   Fox, Stephen ^a,b   Redei, Istvan ^a,b   Green, Fran ^a,b   Raskay, Barbara ^a,b   Amfoh, Kweku ^a,b   Engstrom, Paul F ^a,b   O'Dwyer, Peter J ^a,b  

^a FOX CHASE CANCER CENTER   (United States)

^b Fox Chase Center   (United States)

Author keywords

pancreatic cancer; phase II study; topotecan

Indexed keywords

ANTIEMETIC AGENT; CORTICOSTEROID; PROCHLORPERAZINE; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG ACTIVITY; DRUG TOXICITY; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMATITIS; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; TOPOTECAN;

EID: 0029556666     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/BF00873143     Document Type: Article

References (32)

1. Cancer Statistics 1993
2. Chemotherapy in pancreatic cancer: Results of a controlled, prospective, randomised, multicentre trial
3. SK&F 104864, a water-soluble analog of camptothecin with broad-spectrum activity in preclinical tumor models
4. Camptothecin induced protein-linked DNA breaks via mammalian DNA topoisomerase I
5. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony forming units in vitro
6. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts
7. The current status of camptothecin analogs as antitumor agents
8. Phase I/pharmacokinetic trial of continuous infusion topotecan in patients with refractory solid tumors
9. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly
10. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor
11. Nonparametric estimation from incomplete observations
12. DNA topoisomerases
13. DNA topoisomerase poisons as antitumor drugs
14. Camptothecin, teniposide, or 4′-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells
15. Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells
16. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): Correlation with preclinical studies
17. Synthesis of water-soluble (aminoalkyl) camptothecin analogs: Inhibition of topoisomerase I and antitumor of activity
18. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor
19. Phase I and clinical pharmacologic study of intravenous topotecan (T)
20. A Phase I trial of topotecan (topo) administered by a 24-hr infusion
21. Phase I study of the topoisomerase I inhibitor topotecan (SK&F 104864)
22. Phase I and pharmacologic study of topotecan, an inhibitor of topoisomerase I, with granulocyte-colony stimulating factor (G-CSF): Toxicologic differences between concurrent and post-treatment G-CSF administration
23. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor
24. Prechemotherapy granulocyte-macrophage colony stimulating factor (gm/csf) prevents topotecan-induced neutropenia
25. A Phase II study of CPT-11, a new derivative of camptothecin for previously untreated non-small cell lung cancer
26. Phase II study of CPT-11, a new camptothecin derivative, on gynecological malignancy
27. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer
28. Phase I and pharmacokinetic trial of weekly CPT-11
29. Phase II trial ofCPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study
30. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen